ストックスクリーナーアプリを入手
11.24
4.58%
-0.54
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Allspring Global Investments Holdings LLC Has $3.63 Million Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Levi & Korsinsky Reminds Shareholders of an Investigation into ARS Pharmaceuticals, Inc. (SPRY) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Revolutionary Allergy Spray Gets Massive Insurance Breakthrough: Now Covered for Half of US Patients - StockTitan
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® ... - The Bakersfield Californian
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and - GlobeNewswire
Peregrine Capital Management LLC Invests $4.47 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis - MarketBeat
ARS Pharmaceuticals Presents Data On Neffy Epinephrine Nasal Spray At 2025 AAAAI Meeting - Nasdaq
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) ... - The Bakersfield Californian
Revolutionary Needle-Free Allergy Treatment Shows Superior Results: Clinical Data Reveals Game-Changing Efficacy - StockTitan
U.S. Inflation Readings Show Pick Up in Pricing Pressures - The Globe and Mail
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpHere's What Happened - MarketBeat
Oppenheimer Initiates Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - MarketBeat
(SPRY) Technical Data - Stock Traders Daily
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $615,500.00 in Stock - MarketBeat
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference - GlobeNewswire
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions - Seeking Alpha
Allergy Treatment Pioneer ARS Pharmaceuticals Takes Center Stage at Major Healthcare Conference - StockTitan
Ars Pharmaceuticals director Laura Shawver sells $615k in stock - MSN
Ars Pharmaceuticals director Laura Shawver sells $615k in stock By Investing.com - Investing.com Australia
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3%Here's What Happened - MarketBeat
ARS Pharma Rolls Dice Again On NeffyWill Persistence Pay Off? - RTTNews
3 US Growth Stocks With Significant Insider Ownership - Simply Wall St
(SPRY) Investment Report - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.4% HigherStill a Buy? - MarketBeat
Allegations Against ARS Pharmaceuticals, Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Reach Out - ACCESS Newswire
Neffy Launches Free Epi Nasal Sprayer Program for U.S. Schools - Allergic Living
Equities Analysts Issue Forecasts for SPRY FY2025 Earnings - MarketBeat
What is William Blair's Estimate for SPRY FY2024 Earnings? - MarketBeat
William Blair Has Bullish Forecast for SPRY Q4 Earnings - MarketBeat
ARS Pharmaceuticals Launches neffyinSchools Program - GlobeNewswire
ARS Pharmaceuticals lays down 2025 objectives for epinephrine nasal spray - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lessened by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - The Manila Times
ARS Pharma Launches Free Neffy Nasal Spray Program for U.S. Schools to Combat Allergic Reactions - StockTitan
Cenovus Energy: Analyst Update & AI-Powered Stock Analysis - The Globe and Mail
When (SPRY) Moves Investors should Listen - Stock Traders Daily
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $26.00 - MarketBeat
Raymond James Issues Positive Forecast for ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Analyst Upgrade - MarketBeat
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - MSN
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 7.6% After Analyst Upgrade - MarketBeat
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
ARS Pharmaceuticals shares surge on strong Q4 revenue for allergy spray - Investing.com Canada
ARS Pharmaceuticals (NASDAQ:SPRY) Price Target Raised to $27.00 at Leerink Partners - MarketBeat
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):